Monopar Therapeutics remains a clinical-stage biopharma focused on innovative therapeutic development without current revenue generation but supported by strong liquidity. Its pipeline includes licensed late-stage asset ALXN1840 targeting Wilson disease and proprietary uPAR-targeted radioligand therapies in early-phase trials. Despite sustained operating losses driven by heightened R&D spend, Monopar's cash reserves and prudent capital allocation—including a reverse stock split for Nasdaq compliance—position it well to fund operations through at least 2027. Upcoming regulatory or clinical readouts represent critical milestones, though risks typical to biotech development and funding continue to weigh.